A case report describes a patient with rare genetic lipodystrophy who progressed to fatal LMNA-related cardiomyopathy despite being treated with metreleptin. While metreleptin corrected severe metabolic abnormalities, it did not halt the cardiac disease trajectory. The report highlights the limits of targeted metabolic correction when downstream organ damage is driven by distinct genetic mechanisms, reinforcing the need for disease-modifying strategies beyond leptin pathway normalization. For clinicians and trial designers, the case supports earlier risk stratification for cardiomyopathy in LMNA-associated lipodystrophy and the prioritization of combination or parallel cardiac-focused interventions.